Matsapha – Eswatini is set to distribute Lenacapavir (LEN), a long-acting injectable for HIV prevention, following its official arrival in the country on Monday. The drug, which is administered twice a year, is expected to address adherence challenges often faced with daily oral Pre-Exposure Prophylaxis (PrEP).
Acting Assistant Director of Central Medical Stores (CMS), Sifundo Zwane, said the introduction of LEN marks a significant step forward in the national HIV response. She outlined that CMS has developed a national strategy to ensure the drug is available at all public health facilities. The plan is informed by national HIV data, program targets, and expected uptake trends.
CMS has also implemented a comprehensive supply chain management system, including a buffer-stock strategy, batch-level tracking, and First Expiry, First Out (FEFO) principles to prevent wastage and respond to fluctuations in demand. LEN will be monitored through the national Logistics Management Information System (LMIS) for real-time stock tracking, ensuring timely decision-making and avoiding stockouts.
While LEN does not require cold-chain storage, strict standards for handling and transport will be enforced to maintain its integrity. The first batch has already undergone receiving and quality checks, and is now ready to be dispatched to health facilities as part of the national implementation plan.
Zwane added that close collaboration with the Eswatini National AIDS Programme (ENAP) and supply-chain partners will ensure the safe and efficient distribution of LEN across the country.
Discussion about this post